GlassScriptPhysician profile
Darek S Anderson
NPI 1518932136
$9,719.07
in general payments reported to CMS, 2019-2025
27 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $1,966 · 2023: $2,292 · 2024: $2,557 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,573 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,573.41 |
| Education | $304.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.88 | 2021-2025 | |
| Janssen Biotech, INC. | $1,126.58 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,106.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,006.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $803.04 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $708.04 | 2021-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $522.32 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $492.48 | 2023-2024 | Vtama |
| Leo Pharma INC. | $447.07 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $376.29 | 2024-2025 | Bimzelx |
| Pfizer INC. | $222.94 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $194.98 | 2024-2025 | |
| Hill Dermaceuticals, INC. | $145.23 | 2024-2025 | Tolak |
| Sun Pharmaceutical Industries INC. | $137.97 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $123.28 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.44 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $92.44 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.07 | 2022-2024 | Siliq, Targretin, Duobrii |
| E.R. Squibb & Sons, L.L.C. | $69.33 | 2023-2024 | Sotyktu |
| Incyte Corporation | $61.99 | 2023-2024 | Opzelura |
| Genentech USA, INC. | $58.43 | 2021-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.39 | 2022-2025 | Spevigo |
| Kyowa Kirin, INC. | $43.26 | 2022 | |
| Epi Health, LLC | $24.44 | 2022 | |
| Biowound Solutions, INC. | $16.90 | 2025 | Bio-Connekt |
| Mayne Pharma Commercial LLC | $14.78 | 2023 | |
| Organon LLC | $7.16 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darek Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.